Health Canada Approves Daybue! Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome. DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare neurodevelopmental disorder…. Read More
Health Canada Accepts New Drug Submission for Trofinetide Acadia Pharmaceuticals is pleased to share that Health Canada has accepted their New Drug Submission (NDS) of trofinetide for the treatment of Rett Syndrome. Moreover, the treatment has been granted Priority Review to… Read More
Tag: Trofinetide
DAYBUE – Breaking News
Last Updated: 02/07/2025 by Steve Leave a Comment
Health Canada Approves Daybue! Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome. DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare neurodevelopmental disorder…. Read More
Category: Awareness, News, Top Slider Tags: 2024, Acadia, Trofinetide
Health Canada Accepts a New Drug Submission
Last Updated: 10/25/2024 by Steve Leave a Comment
Health Canada Accepts New Drug Submission for Trofinetide Acadia Pharmaceuticals is pleased to share that Health Canada has accepted their New Drug Submission (NDS) of trofinetide for the treatment of Rett Syndrome. Moreover, the treatment has been granted Priority Review to… Read More
Category: Latest Research, News, Press Releases Tags: 2024, Acadia, Health Canada, Trofinetide